2023-12-22 カロリンスカ研究所(KI)
◆COMMUNITY研究によると、この新型ワクチンはOmicron変異体に特化し、XBBだけでなくBA.2.86などの新しい変異株にも十分な抗体応答をもたらしました。これにより、新型ワクチンは広範なクロスプロテクションを提供し、高齢者やCOVID-19リスクのある人々に対しても効果的である可能性が示唆されています。
<関連情報>
- https://news.ki.se/new-covid-vaccine-induces-good-antibody-response-to-mutated-viral-variants
- https://www.biorxiv.org/content/10.1101/2023.12.21.572575v1
一価XBB.1.5適応BNT162b2 mRNAブースターに対する体液性免疫応答 Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster
Ulrika Marking, Oscar Bladh, Katherina Aguilera, Yiqiu Yang, Nina Greilert-Norin, Kim Blom, Sophia Hober, Jonas Klingstrom, Sebastian Havervall, Mikael Aberg, Daniel J Sheward, Charlotte Thalin
bioRxiv Posted: December 21, 2023
DOI: https://doi.org/10.1101/2023.12.21.572575
Abstract
Continued SARS-CoV-2 evolution and immune escape necessitated the development of updated vaccines, and a monovalent vaccine incorporating the XBB.1.5 variant spike protein is currently being rolled out. Amidst the emergence of the highly mutated BA.2.86 lineage and against the backdrop of pronounced immune imprinting, it is important to characterize the antibody responses following vaccination, particularly in the elderly. Here, we show that the monovalent XBB.1.5-adapted booster vaccination substantially enhanced both binding and neutralising antibody responses against a panel of variants, including BA.2.86, in an older population with four or more previous vaccine doses. Furthermore, neutralizing antibody titers to XBB.1.5 and BA.2.86 were boosted more strongly than titers to historical variants were. Our findings thereby suggest increased vaccine induced protection against both antigenically matched variants, as well as the more distant BA.2.86 variant, and support current vaccine policies recommending a monovalent XBB.1.5 booster dose to older individuals.
